CHCWM – Cancer & Hematology Centers of West Michigan

 (MK-1084-001) Merck

Description:  A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

Mechanism of Action:  KRAS G12C Inhibitor

Target Patient Population:  Advanced solid tumors with KRASG12C mutation

Study Design:  Study Drug is given orally.  Pembrolizumab supplied and given every 3 weeks IV.